Connect your AI

Bio-Techne TECH Fair Value Adjustment To Contingent Consideration Payable

Discontinued — last reported Q3 '25

Fair Value Adjustment To Contingent Consideration Payable at other companies

Coca-Cola Consolidated, Inc.COKE

$53.39M+25.0%

Coca-Cola Consolidated, Inc.COKE

$53.39M+25.0%

Brown & BrownBRO

$5M+225%

Riot Platforms, Inc.RIOT

-$430K+30.1%

BrightSpring Health Services, Inc.BTSG

$0-100%

Comfort Systems USAFIX

$10.37M+176%

Other financials

Income statement

Revenue$311.4M-1.5%

Gross profit$208.3M-2.9%

Operating income$75.5M+95.0%

Net income$51.0M+126%

EPS (diluted)$0.32+129%

Balance sheet

Cash & equivalents$209.8M+49.2%

Total debt$290.3M-31.4%

Total equity$2.1B+3.3%

Total assets$2.6B-3.5%

Cash flow

Operating cash flow$86.7M+111%

CapEx$9.1M-10.2%

Free cash flow$77.6M+150%

Valuation

Market cap$9.07B-11.8%

Enterprise value$9.15B-13.6%

P/E60.6×+13.6×

P/S7.5×-1.0×

Profitability

Gross margin65%-0.8pp

Operating margin14.2%-7.9pp

Net margin10.9%-6.7pp

FCF margin22.3%+4.0pp

Returns & leverage

Return on equity6.5%-3.9pp

Debt / equity0.1×-0.1×

Current ratio4.5×+0.8×

Where this comes from

Reported directly by Bio-Techne in its filing.

Tagged under the XBRL concept tech:FairValueAdjustmentToContingentConsiderationPayable.

The official record: Bio-Techne’s 10-Q, filed May 8, 2025, on SEC EDGAR. View the filing →

Ask your AI about Bio-Techne's fair value adjustment to contingent consideration payable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Bio-Techne's fair value adjustment to contingent consideration payable?: Bio-Techne (TECH) reported fair value adjustment to contingent consideration payable of $0 in Q1 2025.
What does fair value adjustment to contingent consideration payable mean?: This metric tracks changes in the estimated fair value of earn-out payments or contingent liabilities related to past acquisitions. It is a non-cash adjustment that reflects updated expectations regarding the performance of acquired businesses.